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Abstract
Osteoporosis is one of the most prevalent bone diseases 
worldwide and is characterised by high levels of bone 
turnover, a marked loss in bone mass and accumulation 
of microdamage, which leads to an increased fracture 
incidence that places a huge burden on global health 
care systems. Bisphosphonates have been used to treat 
osteoporosis and have shown great success in conserving 
bone mass and reducing fracture incidence. In spite of the 
existing knowledge of the in vivo responses of bone to 
bisphosphonates, the cellular responses to these drugs have 
yet to be fully elucidated. In vitro model systems that allow 
the decoupling of complex highly integrated events, such as 
bone remodelling, provide a tool whereby these biological 
processes may be studied in a more simplified context. 
This study firstly utilised an in vitro model system of bone 
remodelling and comprising all three major cell types of the 
bone (osteocytes, osteoclasts and osteoblasts), which was 
representative of the bone’s capacity to sense microdamage 
and subsequently initiate a basic multicellular unit 
response. Secondly, this system was used to study the effect 
of two commonly utilised aminobisphosphonate treatments 
for osteoporosis, alendronate and zoledronate. We 
demonstrated that microinjury to osteocyte networks being 
treated with bisphosphonates modulates receptor activator 
of nuclear factor kappa-B ligand and osteoprotegerin 
activity, and subsequently osteoclastogenesis. Furthermore, 
bisphosphonates increased the osteogenic potential 
following microinjury. Thus, we have shown for the first 
time that bisphosphonates act at all three stages of bone 
remodelling, from microinjury to osteoclastogenesis and 
ultimately osteogenesis.
Key Words: Bone remodelling, basic multicellular 
unit, microinjury, osteoclastogenesis, osteogenesis, 
osteoporosis, bisphosphonate treatment.
*Address for correspondence:
Garry P. Duffy, BSc, PhD
Department of Anatomy
Royal College of Surgeons in Ireland
123 St. Stephens Green
Dublin 2, Ireland
Telephone Number: +353 1 4022105
FAX Number: +355 1 4022355
E-mail: garryduffy@rcsi.ie
Introduction
Osteoporosis is one of the most prevalent bone diseases 
worldwide and is characterised by high levels of bone 
turnover, a marked loss in bone mass and the accumulation 
of microdamage. Together, these factors culminate in a 
reduced bone density and altered osseous microstructure, 
leading to a decrease in the mechanical competence of 
bone and an increasing susceptibility to fracture (Parfitt, 
2002). In 2000, it was estimated there were approximately 
9 million osteoporosis related fractures globally each year 
(Johnell and Kanis, 2006). In 2005, based on data from 
the previous 25 years (Chrischilles et al., 1994; Hoerger 
et al., 1999, Phillips et al., 1988, Ray et al., 1997), it was 
estimated that there would be over 2 million osteoporosis 
related fractures annually in the United States at a cost of 
>$17 billion, which would grow to greater than 3 million 
fractures per annum at a cost of >$25 billion by 2025 
(Burge et al., 2007; Roche et al., 2005). Osteoporosis is 
a common condition observed in both elderly men and 
women; however, women have a four times greater risk 
of developing osteoporosis, with 30 % of postmenopausal 
women worldwide being affected. The discrepancy 
between sexes is believed to be associated with changes 
in oestrogen content, whereby oestrogen deficiency has 
been associated with increased bone resorption due to 
an increase in activated osteoclasts (Eriksen et al., 1999) 
but also an increase in bone formation that is unable to 
compensate for the enhanced resorption (Brennan et al., 
2011; Jilka et al., 1998).
 Whilst bone remodelling (or bone turnover) may be 
influenced by systemic hormones, such as oestrogen and 
parathyroid hormone (Donahue et al., 2006), other factors 
such as mechanical loading are also known to contribute 
to osteoporosis as it is a major regulator of bone mass 
and geometry with the sensing and transduction of strains 
being essential for the maintenance of healthy bones 
(Bergmann et al., 2010). Individual bones within the 
skeleton experience different mechanical loads, not only 
as a function of their location, but also in response to the 
level of physical activity (Burr et al., 1996), age (Nordin 
et al., 1990) or environment (Zerwekh et al., 1998) of an 
individual. Conditioning of bone to withstand these forces 
occurs through dynamic remodelling that aims to minimise 
stress or strain concentrations (Lanyon, 1987) and provide 
an optimal mechanical structure. Stimulation or activation 
of bone remodelling has been attributed to factors such 
as fluid flow (Kufahl and Saha, 1990; Weinbaum et al., 
1994) and microdamage (Burr et al., 1985; Lee et al., 
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2002; Martin and Burr, 1982) within the bone, which is 
hypothesised to be sensed by osteocytes either through 
mechanotransduction mechanisms (Turner et al., 1994) 
or by the shearing of cellular processes (Hazenberg et al., 
2009; Taylor et al., 2003). This signalling mechanism, 
between mechanically stimulated osteocytes and osteoblast 
progenitors within the bone marrow, is believed to be 
paracrine in nature as osteocytes are spatially isolated 
from the marrow cavity (Hoey et al., 2011). Moreover, 
regions of osteocyte apoptosis have been shown to be 
accompanied by increased local bone turnover and 
targeted bone resorption and are believed to be involved 
in osteoclast precursor recruitment and differentiation in 
vitro (Al-Dujaili et al., 2011). Subsequently, the receptor 
activator of nuclear factor kappa B ligand-receptor 
activator of nuclear factor kappa B- osteoprotegerin 
(RANKL-RANK-OPG) signalling pathway is activated 
(Mulcahy et al., 2011), and in turn mediates the initiation 
of bone remodelling through the synchronous action of the 
basic multicellular unit (BMU) that consists of the main cell 
types involved in bone remodelling: osteoblasts, osteocytes 
and osteoclasts. Accumulation of microdamage within the 
bone due to excessive overloading (Burr et al., 1998), the 
impairment of osteocyte functionality, or perturbations in 
the equilibrium of the resorption and formation arms of the 
BMU (Mashiba et al., 2000), as in osteoporosis, increases 
an individual’s susceptibility to fragility fractures due to 
diminished structural integrity or loss of bone mass and 
thus the mechanical competence of bone.
 Bisphosphonates, synthetic analogues of inorganic 
pyrophosphate, containing a phosphate-carbon-phosphate 
backbone, have been used as drugs to treat osteoporosis 
for the last 30 years (Morris and Einhorn, 2005). They 
act as potent inhibitors of bone resorption, in an effort to 
conserve bone mass and thereby effectively reduce the risk 
of osteoporotic fracture, by the prevention of pre-osteoclast 
recruitment, fusion and differentiation (Russell et al., 
2008). They function by binding tightly to bone mineral, 
where they are internalised by osteoclasts by the process of 
endocytosis during bone resorption. Here, they inactivate 
osteoclast function and induce osteoclast apoptosis. 
Bisphosphonate-treated bone is characterised by fewer 
osteoclast cell numbers, most of which are located away 
from the bone surface, and many of which are undergoing 
apoptosis (Pivonka et al., 2012). Bisphosphonates are not 
metabolised and therefore are either excreted renally or bind 
to hydroxyapatite within the bones where they can remain 
for years (Reginster et al., 2013). This skeletal binding 
affinity has been shown to increase in rank order through 
risedronate, ibandronate, alendronate and zoledronate, with 
higher affinity bisphosphonates becoming rebound more 
quickly thereby increasing skeletal retention (Russell et 
al., 2008). Many studies have reported that bisphosphonate 
treatment increases the degree of mineralisation in bone, 
by facilitating the binding of hydroxyapatite crystals onto 
bone surfaces, principally at the sites of bone remodelling 
(Boivin et al., 2000; Rogers, 2003; Spadaro et al., 2006).
 In vitro model systems that allow the decoupling of 
complex highly integrated events, such as bone remodelling, 
provide researchers with a tool by which biological 
processes may be studied in a more simplified context. 
This will allow researchers to expand the knowledge 
space pertaining to the interactions between individual 
components of the biological system and secondly, create 
a test bed for studying how current treatments exert their 
observed clinical effects and how potential therapeutic 
treatments may modulate inherent biological functions. 
This study aimed to utilise a previously established in 
vitro model system of bone remodelling, that comprises all 
three major cell types of the bone (osteocytes, osteoclasts 
and osteoblasts), in which osteocyte networks can be 
subjected to controlled amounts of microinjury, allowing 
the investigation of bone’s capacity to sense damage and 
initiate a BMU response (Mulcahy et al., 2011). We have 
applied this system to assess the effect of alendronate 
and zoledronate, two aminobisphosphonate treatments 
for osteoporosis that exhibit the highest affinity for bone 
mineral, on the osteocytic response to microdamage and 
the subsequent impact on BMU activation.
Materials and Methods
Cell culture
MLO-Y4 cells, an osteocyte-like cell line originally 
derived from murine long bones (Kato et al., 1997) were 
generously provided by Dr. Linda Bonewald (School 
of Dentistry, University of Missouri, Kansas City, MO, 
USA), and were maintained in α Modified Eagle’s Medium 
(αMEM; Biosera, Uckfield, UK) supplemented with 5 % 
foetal bovine serum (FBS; Biosera, East Sussex, UK), 
5 % iron supplemented calf serum and 1 % penicillin/
streptomycin (P/S; Sigma Aldrich, Dublin, Ireland). Cells 
were cultured in collagen coated flasks (0.15 mg/mL rat 
tail collagen type 1; BD Biosciences, Oxford, UK) at 37 °C 
and 5 % CO2.
 Pre-osteoclasts (RAW 264.7 cells, ATCC, LGC 
Standards, Teddington, UK) were cultured in high glucose 
Dulbecco’s Modified Eagles Medium (DMEM; Sigma 
Aldrich) supplemented with 10 % heat inactivated FBS 
(Biosera) and 1 % P/S.
 Pre-osteoblasts (MC3T3-E1 cells, ATCC, LGC 
Standards, Middlesex, UK) were maintained in αMEM 
supplemented with 10 % FBS, 1 % L-glutamine (Sigma 
Aldrich), and 2 % P/S.
 All cell lines were used in experiments below passage 
20.
Generation of osteocyte microinjury and conditioned 
medium samples
Conditioned media was obtained following application of 
microinjury to gel-embedded osteocyte (MLO-Y4) cells, 
as previously described (Mulcahy et al., 2011). Briefly, 
constructs were prepared by the addition of 1 volume of 
Matrigel Basement Membrane Matrix (BD Biosciences) 
to 1 volume of a collagen solution comprised of 58 % 
Collagen, 27 % 5×DMEM, 2.5 % FBS, 2.5 % calf serum, 
5 % sodium hydroxide (Sigma Aldrich) and 5 % cell 
suspension. An incubation of 5 d was sufficient to facilitate 
cell process network formation. Microinjuries were applied 
through insertion of needles of diameter 160, 300 and 
400 µm into the centre of the hydrogel, creating a planar 
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defect by drawing the needle through the hydrogel at a right 
angle to the point of insertion to create a defect 7 mm in 
length and 5 mm in depth. After 72 h of culture, conditioned 
medium samples were collected. The term microinjury has 
been applied to the planar defects created in this study, 
which are intended to be reflective of microdamage, but due 
to acknowledged differences between the in vitro cultures 
compared to the in vivo scenario, such as osteocyte density 
and process number per osteocyte, we have refrained from 
using the word “microdamage” to represent the defects 
created, as they are not truly of a length scale equating 
to microdamage. The individual cell types involved in 
bone remodelling were spatially decoupled by cultivating 
them separately. Cellular crosstalk was evaluated through 
transfer of conditioned medium from the 3D gel-embedded 
osteocyte (MLO-Y4 cells) network cultures, 72 h post 
microinjury, to the osteoclast (RAW 264.7 cells) monolayer 
cultures, which was then in turn serially transferred to 
pre-osteoblast (MC3T3 cells) monolayer cultures to yield 
doubly conditioned media. Media were also assessed in all 
experiments from gel-embedded osteocytes not subjected 
to injury, termed uninjured cells (i.e. the negative control).
 For all experiments assessing the effects of 
bisphosphonate treatment on pre-osteoclasts and pre-
osteoblasts, 10-5 M concentrations of alendronate or 
zoledronate were added to the culture medium only at the 
time of osteocyte seeding on the gels. Conditioned and 
doubly conditioned media were then taken as described 
previously for treatment of the pre-osteoclast and pre-
osteoblast cells.
Cell migration assays
In order to assess whether osteocyte injury or osteocyte 
injury/osteoclastogenesis, with and without 10-5 M 
bisphosphonate treatment, stimulates the migration of 
pre-osteoclast and pre-osteoblast cells respectively towards 
a site of damage, a cell migration assay was performed. 
This assay is based on the concept that following a period 
of serum starvation, cells will migrate through a porous 
membrane towards a stimulus. Under serum free conditions, 
1 × 104 pre-osteoclasts/pre-osteoblasts were cultured on 
the upper side of 8 μm pore hanging cell culture inserts 
(Millipore, Cork, Ireland). Following a 2 h incubation, 
serum free medium was replaced with conditioned/doubly 
conditioned medium from injury experiments (n = 3 per 
injury size). Media were also assessed from gel-embedded 
osteocytes not subjected to injury, termed uninjured cells. 
Controls were serum free medium (OptiMEM; Invitrogen, 
Dublin, Ireland) and cell culture medium containing 10 % 
FBS. Cells were incubated for 18 h, following which cell-
seeded membranes were fixed in 4 % formalin for 10 min, 
and stained with haematoxylin for 10 min. The membrane 
was then removed and mounted on a glass slide, bottom 
side down. Cell migration was quantified by counting the 
cells on the bottom side of the membrane in 5 random fields 
(n = 3 per treatment group).
Osteoclastogenesis
Pre-osteoclasts were seeded at a density of 4 × 104 cells/
well in 12-well adherent plates (Cruinn Diagnostics, 
Dublin, Ireland) or on poly-D-lysine (1 M)-coated 
chamber-slides. Pre-osteoclast cell culture medium was 
replaced with osteocyte conditioned medium, with or 
without 10-5 M bisphosphonate treatment, 24 h after 
seeding. Conditioned medium was changed every 3 days. 
After 21 d, tartrate-resistant acid phosphatase (TRAP) 
activity was quantified (n = 3 per treatment group) by 
removing the culture medium from pre-osteoclast cultures 
and incubating it for 1 h in 1 mM citrate solution at 37 °C. 
This culture medium solution (20 µL) was then added to 
50 µL of a solution containing 100 mmol p-nitrophenyl 
phosphate (pNPP) (Sigma Aldrich), 200 mmol sodium 
citrate (Sigma Aldrich, Dublin, Ireland) and 80 mmol/L 
sodium tartrate (Sigma Aldrich) in a 96-well plate, and 
incubated for a further 30 min at 37 °C. NaOH (20 µL 
of 1 M solution) was then added to stop the reaction 
and absorbance was read at 405 nm by spectroscopy. 
TRAP staining was performed using a Leukocyte Acid 
Phosphatase Kit (Sigma Aldrich) in accordance with the 
manufacturer’s instructions. Furthermore, the number of 
TRAP positive multinucleated cells were quantified, from 
3 random fields of view, at 20× magnification, and their 
frequency expressed at a percentage of cells within the 
field of view (n = 3 per treatment group).
Osteoblast differentiation
Pre-osteoblasts were seeded at a density of 4 × 104 
cells in 6 well plates. Cells were allowed to attach 
for 24 h prior to replacing growth medium with a 1:1 
ratio of doubly conditioned medium from microinjury/
osteoclastogenesis experiments, with or without 10-5 M 
bisphosphonate treatment, combined with either growth 
or osteogenic medium. Osteogenic medium was prepared 
by the addition of ascorbic acid (50 μg/mL; Sigma 
Aldrich), β-glycerophosphate (10 mM; Sigma Aldrich) 
and dexamethasone (100 nM; Sigma Aldrich) was added 
to standard αMEM supplemented with 10 % FBS, 1 % 
L-glutamine and 2 % penicillin/streptomycin. Cells were 
cultured for 21 d at 5 % CO2 and 37 °C.
 To assess osteogenic differentiation, treatment medium 
was removed from pre-osteoblasts cultured for 21 d, cells 
were rinsed in phosphate buffered saline (PBS; Sigma 
Aldrich) and 500 µL of 1 M HCl added to each well. 
Cells were manually detached using a cell scraper and the 
resulting cell suspension placed into a 1.5 mL cryovial. 
Wells were then washed a second time with an additional 
500 µL of 1 M HCl and this was added to the initial 
cryovial. Samples were left overnight at 4 °C. Calcium 
deposition was quantified using the Calcium Liquicolor 
Kit (Stanbio Laboratories, Boerne, TX, USA) according 
to the manufacturer’s protocol and calcium concentration 
was deduced using a standard curve (n = 3 per treatment 
group).
Effect of bisphosphonate treatment on RANKL and 
OPG expression levels after osteocyte microinjury
Studies were performed to determine an optimum dose of 
bisphosphonate treatment (data not shown). As a result, a 
10-5 M concentration of each bisphosphonate, consistent 
with concentrations suggested in the literature (Naidu et 
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al., 2008), was chosen to be the optimum dose to maintain 
osteocyte viability whilst still stimulating a temporal 
pharmacological response.
 Gel-embedded osteocytes were incubated using 
OptiMEM serum-free medium, supplemented with 
10-5 M concentration of both alendronate and zoledronate. 
Samples were taken at 24 h intervals over a 72 h time 
period. RANKL and OPG were quantified by means of 
single site specific ELISA (Mouse RANKL and OPG 
ELISA, R&D Systems) under manufacturers’ instructions. 
Cultures (n = 3) were assayed at each injury level, in 
addition to non-injured controls.
Statistical analysis
All experiments contained n = 3 technical repeats and 
were performed in triplicate. All data were analysed for 
significance (p ≤ 0.05) using one way ANOVA followed 
by a post-hoc Tukey test, to compare means between 
injured and uninjured groups and between drug treated 
and non-drug treated groups under the same experimental 
parameters.
Results
Development of an osteocyte-BMU in vitro model
The initial set of studies aimed to identify the required 
microinjury size needed in the gel-embedded osteocyte 
networks to yield conditioned medium capable of 
recruiting and differentiating pre-osteoclasts, which in turn, 
would be capable of recruiting pre-osteoblasts and yielding 
increased mineralisation when using doubly conditioned 
media (media exposed to osteocytes and pre-osteoclasts), 
thereby mimicking the in vivo scenario. Fig. 1 represents 
a diagrammatic representation depicting the in vitro bone 
remodelling system designed to study the relationship 
between osteocyte signalling in response to microinjury 
and BMU activation and function.
The effect of microinjury size to osteocyte networks on 
pre-osteoclast migration and differentiation
Conditioned media were taken from gel-embedded 
osteocyte networks, subjected to microinjury widths of 
160, 300 or 400 µm in addition to uninjured cells after 
72 h, and added to pre-osteoclasts to assess migration 
and differentiation potential. A significant increase in pre-
osteoclast cell migration was observed, in response to the 
conditioned medium from microinjured osteocyte networks 
that experienced injury widths of 300 and 400 µm, in 
comparison to the smaller injury width or the undamaged 
control (Fig. 2a). Osteoclastogenesis, as measured by 
TRAP activity, was significantly increased for all injury 
sizes in comparison to the undamaged control (Fig. 2b). 
TRAP staining of pre-osteoclasts suggested the presence 
of larger multinucleated cells was greatest in 300 µm and 
400 µm injury widths, when compared to the 160 µm injury 
width and undamaged control (Fig. 2c), suggesting the 
larger microinjury widths exerted the most potent effects 
on pre-osteoclasts.
The effect of doubly conditioned medium from microinjury 
induced osteoclastogenesis on pre-osteoblast migration 
and differentiation
Doubly conditioned medium (medium exposed to 
osteocytes and pre-osteoclasts) was then either directly 
used for pre-osteoblast migration studies or combined in 
a 1:1 ratio with osteoblast growth or osteogenic medium, 
to examine the effect on pre-osteoblast mineralisation. 
Pre-osteoblast migration was proportional to osteocyte 
network injury width, with doubly conditioned medium 
from a 400 µm injury size showing significantly increased 
levels of migration, compared to the undamaged control 
Fig. 1. Diagrammatic representation of the in vitro bone remodelling system for studying the relationship between 
osteocyte signalling in response to microinjury and BMU activation and function. The individual cell types involved 
in bone remodelling are spatially decoupled by cultivating them separately. Cellular crosstalk is then evaluated 
through transfer of conditioned medium from the 3D gel embedded osteocyte (MLO-Y4 cells) network cultures, post 
microinjury, to the pre-osteoclast (RAW 264.7 cells) monolayer cultures, which are then in turn serially transferred 
to pre-osteoblast (MC3T3 cells) monolayer cultures.
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(Fig. 3a). Significantly higher levels of calcification were 
noted in pre-osteoblasts exposed to doubly conditioned 
medium from 400 µm injury sizes, in comparison to other 
injury sizes when cultured in the absence of osteogenic 
medium. When osteogenic medium was utilised, all injury 
sizes expressed similar levels of calcification (Fig. 3b). 
These data suggest that microinjury sizes of 400 µm alone 
were sufficient to stimulate pre-osteoblast mineralisation.
Using an in vitro osteocyte-BMU assay system to study the 
effect of bisphosphonate treatment
Based on the studies described above, a 400 µm injury 
width was the only in vitro microinjury size tested capable 
of inducing cellular crosstalk between the different 
cell types that replicated the expected in vivo response. 
Thus, further experiments aiming to study the role of 
bisphosphonates were conducted using this injury size.
The presence of bisphosphonates during osteocyte 
network microinjury modulates osteoclast migration and 
differentiation
The treatment of gel-embedded osteocyte networks with 
alendronate did not reduce migration of pre-osteoclasts 
in response to a microinjury size of 400 µm, whilst 
zoledronate surprisingly showed a significant increase 
in the level of pre-osteoclast migration (Fig. 4a). 
Interestingly, the treatment of gel-embedded osteocyte 
networks with alendronate or zoledronate significantly 
decreased osteoclastogenesis as measured by TRAP 
activity in undamaged controls. Microinjuries of 400 µm 
were still capable of inducing osteoclast differentiation 
in bisphosphonate treated groups; however, the levels of 
TRAP activity (Fig. 4b) and TRAP positive cells were 
significantly less than that observed for the non-treated 
groups post microinjury (Fig. 4c).
Doubly conditioned medium from microinjury induced 
osteoclastogenesis under bisphosphonate treatment 
conditions modulates pre-osteoblast migration and 
differentiation
Gel-embedded osteocyte networks were subjected to a 
microinjury width of 400 µm in the presence or absence 
of bisphosphonate treatment. After 72 h, conditioned 
medium was collected and used in osteoclastogenesis 
assays (as described previously). This doubly conditioned 
medium was then either used for pre-osteoblast migration 
studies or utilised to examine the effect on pre-osteoblast 
mineralisation. Pre-osteoblast migration significantly 
increased in all treatment groups in response to microinjury, 
compared to undamaged controls. Significantly higher 
levels of cell migration were noted in the zoledronate 
microinjured group, in comparison to the untreated 
and alendronate treated microinjured groups (Fig. 5a). 
Bisphosphonate treatment significantly increased calcium 
deposition by pre-osteoblasts over a 21 d period, in 
both the undamaged and microinjured groups, with the 
Fig. 2. The effect of injury size within gel embedded osteocyte networks on pre-osteoclast migration and differentiation. 
Osteocyte cultures were subjected to microinjury having widths of 160, 300 or 400 µm. After 72 h, conditioned 
medium was collected and used to assess (a) the chemotaxic properties on pre-osteoclasts, (A, p ≤ 0.05 versus 160 µm 
injuries and undamaged cells), (b) the induction of osteoclastogenesis after 21 d of culture, as quantitatively measured 
by TRAP activity, (A, p ≤ 0.05 versus uninjured control), or (c) qualitatively measured by TRAP staining, which 
suggested the presence of large multinucleated cells was greatest in 300 and 400 µm samples. Error bars represent 
the standard deviation, n = 3.
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microinjured groups having a further significant increase 
in calcium deposition levels, suggesting an additive effect 
of microinjury with bisphosphonate treatment (Fig. 5b).
The effect of bisphosphonate treatment on the RANKL-
RANK-OPG pathway
Gel-embedded osteocyte networks were subjected to 
microinjury having an injury width of 400 µm in the 
presence or absence of bisphosphonate treatment. Secreted 
RANKL and OPG protein expression levels were measured 
by ELISA. Bisphosphonate treatment significantly reduced 
both cytokines in uninjured and microinjured samples 
(Fig. 6a and b).
Discussion
It is well known that bone is capable of detecting and 
repairing microcracks and other forms of microscopic 
damage and that bone remodelling by BMUs is stimulated 
by microdamage (Burr et al., 1985; Hazenberg et al., 
2009; Martin, 2002; Verborgt et al., 2000). The detection 
of microdamage and subsequent activation of the BMU 
to initiate bone remodelling is believed to be facilitated 
by osteocytes, as a function of their mechanosensory 
and mechanostimulatory attributes, either through a 
mechanotransduction mechanism (Turner et al., 1994) 
or, as hypothesised by our group, by a so called “scissors 
Fig. 3. The effect of microinjury induced osteoclastogenesis 
on pre-osteoblast migration and differentiation. Gel 
embedded osteocyte networks were subjected to 
microinjury having widths of 160, 300 or 400 µm. After 
72 h, conditioned medium was collected and used in 
osteoclastogenesis assays. This doubly conditioned 
medium was then either directly used to evaluate pre-
osteoblast migration (a) (A, p ≤ 0.05 versus serum free 
control; B, p ≤ 0.05 versus all other groups) or combined 
in a 1:1 ratio with osteoblast growth or osteogenic medium 
and used to assess its osteogenic differentiation potential 
(b) (A, p ≤ 0.05 versus cell culture medium). Error bars 
represent the standard deviation, n = 3.
Fig. 4. The effect of microinjury within osteocyte cultures 
in the presence of bisphosphonates on pre-osteoclast 
migration and differentiation. Gel embedded osteocyte 
networks were subject to microinjury having a width of 
400 µm in the presence of alendronate or zoledronate. After 
72 h, conditioned medium was collected and used to assess 
either the chemotaxic properties on pre-osteoclasts (a) (A, 
p ≤ 0.01 versus all other groups; B, p ≤ 0.05 versus 400 µm 
+ culture medium), or the induction of osteoclastogenesis 
after 21 d of culture, as quantitatively measured by TRAP 
activity (b) (A, p ≤ 0.05 versus cell culture medium; B, 
p ≤ 0.05 decrease versus cell culture medium for same 
injury size) or quantification of TRAP staining (c) (A, 
p ≤ 0.01 versus all other groups; B, p ≤ 0.05 decrease 
versus cell culture medium for same injury size). Error 
bars represent the standard deviation, n = 3.
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Fig. 5. The effect of bisphosphonate-modulated 
microinjury-induced osteoclastogenesis on pre-
osteoblast migration and differentiation. Pre-osteocyte 
cultures were subject to microinjury having a width of 
400 µm in the presence of alendronate or zoledronate. 
After 72 h, conditioned medium was collected and 
used in osteoclastogenesis assays. This doubly-
conditioned medium was then either directly used 
to evaluate pre-osteoblast migration (a) (A, p ≤ 0.05 
decrease versus all 400 µm treated groups; B, p ≤ 0.01 
versus 400 µm + culture medium) or combined in a 
1:1 ratio with osteoblast growth medium and used to 
assess its osteogenic differentiation potential (b) (A, 
p ≤ 0.05 versus all other treatment groups except for 
uninjured + culture medium; B, p ≤ 0.05 versus cell 
culture medium group for the same injury size). Error 
bars represent the standard deviation, n = 3.
Fig. 6. The effect of bisphosphonate 
concentration on RANKL and 
OPG protein expression levels 
after osteocyte injury. Osteocyte 
cultures were supplemented with 
10-5 M alendronate or zoledronate 
concentrations and subject  to 
microinjury having a width of 
400 µm. RANKL (a) and OPG 
(b) protein expression levels were 
quantified by ELISA (A, p ≤ 0.05 
versus bisphosphonate-treated groups 
for the same injury size). Error bars 
represent the standard deviation, 
n = 3.
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model” that involves the shearing of cellular processes 
(Hazenberg et al., 2009; Taylor et al., 2003). In order to 
study this behaviour in vitro, a model allowing controlled 
levels of injury and damage to osteocyte networks was 
developed in-house, in the absence of the bone tissue 
matrix (Mulcahy et al., 2011). This study showed that this 
in vitro microinjury can modulate the RANKL-RANK-
OPG signalling pathway (Mulcahy et al., 2011) in a manner 
indicative of the in vivo response, which is associated with 
the initiation of bone remodelling through the synchronous 
action of the BMU. Bone remodelling consists of several 
stages, which include activation, resorption and formation. 
Activation refers to the stage by which an influx of 
osteoclast precursor cells infiltrates the area of osteocyte 
rupture and fuse to form giant, active osteoclasts. These 
differentiated osteoclasts then polarise to bone and release 
lytic enzymes, which break down bone, under the control 
of RANKL-RANK interaction (Katagiri and Takahashi, 
2002). Finally, formation of new bone, by the infiltration 
of pre-osteoblasts, leads to the secretion of osteoid, which 
becomes mineralised by calcium and phosphates in 
peripheral fluids. This occurs following release of OPG, 
which stops RANKL-RANK interaction, and stimulates 
the influx of pre-osteoblasts.
 This study describes the successful development of 
an in vitro model capable of mimicking this interactive 
crosstalk between sensory osteocytic networks and the 
osteoclastogenic and osteogenic activities of the BMU. 
We showed that in response to microinjury sizes of 
400 µm, pre-osteoclast migration was increased, and 
osteoclast differentiation, as measured by TRAP activity, 
was significantly upregulated. Furthermore, doubly-
conditioned medium was capable of enhancing pre-
osteoblast migration and pre-osteoblast differentiation, as 
measured by the deposition of calcium.
 In vitro models, as developed in this study, offer 
researchers a potential means by which complex systems 
such as bone remodelling can be decoupled and the effects 
of pharmaceutical agents on individual components of the 
system can be analysed. For example, since the early 1990s 
bisphosphonates have yielded significant potential and 
have shown great success in the treatment of osteoporosis, 
as well as other bone diseases, including metastatic bone 
disease, osteopenia and Paget’s disease (Morris and 
Einhorn, 2005). In spite of the existing knowledge of 
the in vivo responses of bone to bisphosphonates, it is 
well recognised that the cellular responses to these drugs 
require further investigation. In this study, an in vitro 
model system was applied to investigate the effect of two 
aminobisphosphonates, alendronate and zoledronate, on 
osteocyte stimulation in response to microinjury and the 
subsequent impact upon the cells constituting the BMU.
 The changes observed in the RANKL-RANK-OPG 
signalling pathway, as a function of bisphosphonate 
treatment, directly resulted in reduced osteoclast activity 
as measured by TRAP activity, as observed by other groups 
previously in vitro (Boonekamp et al., 1986; Kimachi et al., 
2011; Li et al., 2011), in line with the expected method of 
action for these drugs in vivo. However, previous in vivo 
studies have suggested that alendronate is a less potent 
inhibitor of osteoclast activity than zoledronate (Watts and 
Diab, 2010), though the results herein suggest there is no 
difference between the two bisphosphonates when tested 
in vitro. It is important to point out that the differences 
observed in inhibition of osteoclast activity in vivo relies 
on a number of factors that primarily includes the method 
of bisphosphonate administration (i.e. intravenous versus 
oral) and also the different bioavailability. For example, 
oral bisphosphonates have very limited bioavailability 
due to their poor lipophilicity, with less than 1 % of orally 
taken bisphosphonates being absorbed in the gut (Ruza et 
al., 2013). As a result, the potency is also different but in 
a comparable order of magnitude. This was demonstrated 
in a study by Orwoll et al. (2010) that showed similar 
increased bone density and decreased bone turnover 
markers when comparing the safety and efficacy of a 
once-yearly intravenous infusion of 5 mg zoledronic 
acid versus a once-weekly 70 mg oral alendronate 
in the treatment of male osteoporosis. The effect of 
bisphosphonate treatment on pre-osteoblast migration 
and differentiation was subsequently evaluated. Both 
zoledronate and alendronate significantly increased both 
pre-osteoblast migration and differentiation in response 
to microinjury. These findings are in line with previous 
reports suggesting that aminobisphosphonates, including 
alendronate and zoledronate, have stimulatory effects on 
osteoblast differentiation and proliferation (Pan et al., 2004; 
Reinholz et al., 2000). Although the exact mechanism by 
which bisphosphonates affect osteoblasts remains elusive, 
zoledronic acid has been shown to inhibit the mevalonate 
pathway thereby inducing human osteoblast differentiation 
(Reinholz et al., 2002). Inhibition of this pathway also 
prevents osteoclasts from attaching to the bone surface 
and therefore resorbing bone (Fisher et al., 2000).
 This study also showed that the release of two of the 
principal cytokines involved in bone remodelling, RANKL, 
which functions by stimulating osteoclastogenesis, 
and its antagonist, OPG, which sequesters RANKL 
activity, stimulating osteoblastogenesis (Lacey et al., 
1998; Simonet et al., 1997) were significantly reduced 
in response to bisphosphonate treatments. These results 
are reflective of the work of others (Giner et al., 2011; 
Kimachi et al., 2011; Koch et al., 2012), who observed 
that aminobisphosphonates, including alendronate and 
zoledronate, posed a modulatory effect on RANKL activity 
in osteoblastic cells. Considering that in this model the 
effect of bisphosphonates on an osteocytic network is 
being assessed, the results may be significant in further 
demonstrating the biochemical effect of osteoporotic 
drugs, most notably so in a model of microinjury in bone. 
However, the reduction in OPG, in both alendronate and 
zoledronate-treated samples, is something that has not 
been extensively observed to date and provides further 
mechanistic information regarding the action of such drugs.
 In conclusion, the in vivo effects of bisphosphonates are, 
at present, well documented, and treatment of osteoporosis 
using bisphosphonates has shown great promise with 
regard to decreasing osteoclast activity and increasing 
bone mineral density. However, the cellular response to 
bisphosphonates, in an environment mimicking microinjury 
of the osteocyte network, has yet to be clarified. This study, 
using a novel in vitro model of bone remodelling, which 
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allowed the spatial decoupling of the different cell types 
involved, has shown for the first time that microinjury, 
under the treatment of aminobisphosphonates, has a 
modulatory effect on RANKL and OPG activity, and 
thus on osteoclastogenesis. Furthermore, the presence of 
bisphosphonates was shown to increase the osteogenic 
potential of microinjury. Thus, we have shown that 
bisphosphonates act at all three stages of bone remodelling, 
from microinjury to osteoclastogenesis and ultimately 
osteogenesis.
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Discussion with Reviewer
Reviewer I: For this model, why did the authors not 
co-culture the osteoblasts and osteoclasts together from 
the beginning in one dish or plate and then transfer the 
microdamage conditioned media?
Authors: In order to test this model at the most basic level, 
we chose to assess the individual cell types to gain a basic 
understanding of how the individual cell types function 
during bone remodelling. It was agreed that were a co-
culture to be evaluated it would introduce a further level 
of complexity that was beyond the scope of this particular 
study but may be of interest in future studies.
Editor’s Note: Scientific Editor in charge of the paper: 
Martin Stoddart.
